PURPOSE
To explore the efficacy, safety, and predictability of topography-guided laser epithelial keratomileusis (LASEK) and LASIK treatments using the ALLEGRO Oculyzer (rotating Scheimpflug image-based) as compared to the ALLEGRO Topolyzer (Placido disk-based) platform (WaveLight AG).
METHODS
In this retrospective, non-comparative case series, 72 eyes were treated using Oculyzer data and 71 eyes were treated using Topolyzer data. Seventy-nine men and 64 women ranging in age from 21 to 63 years were included in the study. The 6-month postoperative uncorrected visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA) of patients were compared to the preoperative values. The data analysis was stratified based on the preoperative refractions, separating patients into three categories: myopes, hyperopes, and mixed astigmatics.
RESULTS
Of the preoperative myopes in the Oculyzer group, 76% remained the same, 5% lost 1 line, 14% gained 1 line, and 5% gained 2 lines of visual acuity at 6 months. In the Topolyzer group, 69% remained the same, 25% gained 1 line, and 6% gained 2 lines of BSCVA. Using the Oculzyer, 95% of myopes, 80% of hyperopes, and 60% of patients with mixed astigmatism were within ±0.50 diopters (D) of target refraction. Using the Topolyzer, 88% of myopes, 78% of hyperopes, and 50% of patients with mixed astigmatism were within ±0.50 D of target. The outcomes of the preoperative hyperopes and patients with mixed astigmatism are similarly reported. The difference in outcomes between the Oculyzer and Topolyzer cohorts in the myopes and patients with mixed astigmatism was not statistically significant. In the hyperopes, patients treated with the Oculyzer had superior UCVA to those treated with the Topolyzer platform.
CONCLUSIONS
This case series demonstrates that the Oculyzer and Topolyzer are both effective tools in topography-guided corneal excimer laser surgery. In myopes and patients with mixed astigmatism, both systems were comparable in efficacy and safety. In the hyperopes, the resultant UCVA in the Oculyzer cohort was slightly superior. [J Refract Surg. 2010;26(7):478-485.]
AUTHORS
From Wellington Eye Clinic, Dublin, Ireland (Cummings); and WaveLight AG, Erlangen, Germany (Mascharka).
Dr Cummings has no commercial or proprietary interest in the materials presented herein. Ms Mascharka is Ophthalmology Product Manager for WaveLight AG (Alcon Laboratories) and has a financial interest in the company.
Assistance with the preparation of this paper was provided by WaveLight AG.
Correspondence: Arthur B. Cummings, MD, Wellington Eye Clinic, Ste 36, Beacon Hall, Beacon Court, Sandyford, Dublin 18, Ireland. Tel: 353 1 2930470; Fax: 353 1 2935978; E-mail: abc@wellingtoneyeclinic.com
Received: February 4, 2009; Accepted: July 16, 2009
Posted online: August 17, 2009
doi:10.3928/1081597X-20090814-05
